Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

Jesper van Breeschoten; Alfons J.M. van den Eertwegh; Doranne L. Hilarius; John B. Haanen; Christian U. Blank; Maureen J.B. Aarts; Franchette W.P.J. van den Berkmortel; Jan Willem B. de Groot; Geke A.P. Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S. van Rijn; Marion A. Stevense-den Boer; Astrid A.M. van der Veldt; Gerard Vreugdenhil; Marye J. Boers-Sonderen; Damjan Manevski; Karijn P.M. Suijkerbuijk; Michel W.J.M. Wouters; Liesbeth C. de Wreede

doi:10.1016/j.ejca.2023.01.006

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

16 Downloads (Pure)

Abstract

INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups.

METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state.

RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response.

CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.

Original language	English
Pages (from-to)	132-143
Number of pages	12
Journal	European Journal of Cancer
Volume	182
DOIs	https://doi.org/10.1016/j.ejca.2023.01.006
Publication status	Published - Mar 2023

Keywords

Advanced melanoma
Multistate model
Older patients
Population mortality
Relative survival
Response status

Access to Document

10.1016/j.ejca.2023.01.006Licence: CC BY

1-s2.0-S095980492300014X-mainFinal published version, 1.34 MBLicence: CC BY

Cite this

van Breeschoten, J., van den Eertwegh, A. J. M., Hilarius, D. L., Haanen, J. B., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Stevense-den Boer, M. A., van der Veldt, A. A. M., Vreugdenhil, G., Boers-Sonderen, M. J., Manevski, D., Suijkerbuijk, K. P. M., Wouters, M. W. J. M., & de Wreede, L. C. (2023). Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry. European Journal of Cancer, 182, 132-143. https://doi.org/10.1016/j.ejca.2023.01.006

@article{480d7b7a35134e0dbe13c25fbf5ca3c3,

title = "Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry",

abstract = "INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups.METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state.RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response.CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.",

keywords = "Advanced melanoma, Multistate model, Older patients, Population mortality, Relative survival, Response status",

author = "{van Breeschoten}, Jesper and {van den Eertwegh}, {Alfons J.M.} and Hilarius, {Doranne L.} and Haanen, {John B.} and Blank, {Christian U.} and Aarts, {Maureen J.B.} and {van den Berkmortel}, {Franchette W.P.J.} and {de Groot}, {Jan Willem B.} and Hospers, {Geke A.P.} and Ellen Kapiteijn and Djura Piersma and {van Rijn}, {Rozemarijn S.} and {Stevense-den Boer}, {Marion A.} and {van der Veldt}, {Astrid A.M.} and Gerard Vreugdenhil and Boers-Sonderen, {Marye J.} and Damjan Manevski and Suijkerbuijk, {Karijn P.M.} and Wouters, {Michel W.J.M.} and {de Wreede}, {Liesbeth C.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = mar,

doi = "10.1016/j.ejca.2023.01.006",

language = "English",

volume = "182",

pages = "132--143",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

van Breeschoten, J, van den Eertwegh, AJM, Hilarius, DL, Haanen, JB, Blank, CU, Aarts, MJB, van den Berkmortel, FWPJ, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Piersma, D, van Rijn, RS, Stevense-den Boer, MA, van der Veldt, AAM, Vreugdenhil, G, Boers-Sonderen, MJ, Manevski, D, Suijkerbuijk, KPM, Wouters, MWJM & de Wreede, LC 2023, 'Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry', European Journal of Cancer, vol. 182, pp. 132-143. https://doi.org/10.1016/j.ejca.2023.01.006

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry. / van Breeschoten, Jesper; van den Eertwegh, Alfons J.M.; Hilarius, Doranne L. et al.
In: European Journal of Cancer, Vol. 182, 03.2023, p. 132-143.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

AU - van Breeschoten, Jesper

AU - van den Eertwegh, Alfons J.M.

AU - Hilarius, Doranne L.

AU - Haanen, John B.

AU - Blank, Christian U.

AU - Aarts, Maureen J.B.

AU - van den Berkmortel, Franchette W.P.J.

AU - de Groot, Jan Willem B.

AU - Hospers, Geke A.P.

AU - Kapiteijn, Ellen

AU - Piersma, Djura

AU - van Rijn, Rozemarijn S.

AU - Stevense-den Boer, Marion A.

AU - van der Veldt, Astrid A.M.

AU - Vreugdenhil, Gerard

AU - Boers-Sonderen, Marye J.

AU - Manevski, Damjan

AU - Suijkerbuijk, Karijn P.M.

AU - Wouters, Michel W.J.M.

AU - de Wreede, Liesbeth C.

PY - 2023/3

Y1 - 2023/3

N2 - INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups.METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state.RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response.CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.

AB - INTRODUCTION: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma patients. The aim of this study was to assess population mortality after different response states in advanced melanoma patients in the Netherlands, and analyse the contribution of disease and population mortality for different age groups.METHODS: We selected patients diagnosed between 2013 and 2019 with unresectable IIIC or stage IV melanoma, registered in the Dutch Melanoma Treatment Registry. A multi-state model with response states integrating population mortality was fitted. One-year landmark analyses were performed to assess outcomes after each response state.RESULTS: Overall, 5119 patients were selected. Five-year probabilities of melanoma-related mortality in patients alive in complete response at one year after diagnosis increased with age, and was 17.2% (95% confidence interval: 13.0-21.4) for patients aged <65 years and 28.7% (95% confidence interval: 24.3-33.1) in patients aged ≥80 years. Population mortality only played a large role for older patients (75 years and above) alive at 1 year after diagnosis with a partial or complete response.CONCLUSION: Even though survival outcomes of advanced melanoma patients have improved over the last decade, the vast majority of patients still die due to melanoma-related mortality.

KW - Advanced melanoma

KW - Multistate model

KW - Older patients

KW - Population mortality

KW - Relative survival

KW - Response status

UR - http://www.scopus.com/inward/record.url?scp=85147863592&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2023.01.006

DO - 10.1016/j.ejca.2023.01.006

M3 - Article

C2 - 36773402

AN - SCOPUS:85147863592

SN - 0959-8049

VL - 182

SP - 132

EP - 143

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this